Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

GLYC

GlycoMimetics Inc

Dec 07 • 02:44PM ET

1.60

Dollar change +0.03
Percentage change 1.91	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.64	Insider Own	10.60%	Shs Outstand	64.39M	Perf Week	-2.44%
Market Cap	103.02M	Forward P/E	-	EPS next Y	-0.63	Insider Trans	0.97%	Shs Float	57.57M	Perf Month	19.40%
Income	-38.07M	PEG	-	EPS next Q	-0.15	Inst Own	46.66%	Short Float / Ratio	1.53% / 7.35	Perf Quarter	8.11%
Sales	0.00M	P/S	-	EPS this Y	31.84%	Inst Trans	-1.81%	Short Interest	0.88M	Perf Half Y	-11.11%
Book/sh	0.72	P/B	2.21	EPS next Y	-3.85%	ROA	-69.74%	Target Price	5.50	Perf Year	-27.93%
Cash/sh	0.77	P/C	2.09	EPS next 5Y	-	ROE	-80.42%	52W Range	1.11 - 4.16	Perf YTD	-47.19%
Dividend	-	P/FCF	-	EPS past 5Y	4.69%	ROI	-81.32%	52W High	-61.54%	Beta	2.15
Dividend %	-	Quick Ratio	8.14	Sales past 5Y	-36.42%	Gross Margin	-1282.66%	52W Low	44.14%	ATR	0.11
Employees	39	Current Ratio	8.14	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	57.47	Volatility	10.36% 8.66%
Optionable	Yes	Debt/Eq	0.02	EPS Q/Q	12.05%	Profit Margin	-	Rel Volume	0.30	Prev Close	1.57
Shortable	Yes	LT Debt/Eq	0.01	Earnings	Nov 03 BMO	Payout	-	Avg Volume	119.62K	Price	1.60
Recom	1.00	SMA20	8.66%	SMA50	15.36%	SMA200	3.50%	Volume	29,599	Change	1.91%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-12-21	Upgrade	Jefferies	Hold → Buy	$3 → $4
Nov-14-19	Initiated	ROTH Capital	Buy	$12
Aug-05-19	Downgrade	SunTrust	Buy → Hold	$23 → $5
Aug-05-19	Downgrade	Piper Jaffray	Overweight → Neutral	$20 → $6
Aug-05-19	Downgrade	Jefferies	Buy → Hold
Apr-12-19	Initiated	Piper Jaffray	Overweight	$20
Dec-18-18	Initiated	H.C. Wainwright	Buy	$24
Jul-26-16	Initiated	SunTrust	Buy
Mar-17-15	Reiterated	Stifel	Buy	$13 → $14

Nov-09-23 07:00AM	GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference (Business Wire) -10.45%
Nov-05-23 08:51AM	GlycoMimetics, Inc. (NASDAQ:GLYC) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-04-23 01:48AM	Q3 2023 GlycoMimetics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-03-23 10:33AM	GlycoMimetics Inc (GLYC) Reports Q3 2023 Financial Results (GuruFocus.com)
07:07AM	GlycoMimetics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023 (Business Wire)
Oct-23-23 08:30AM	Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board (PR Newswire) -7.14%
Oct-20-23 07:00AM	GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023 (Business Wire)
Sep-06-23 07:00AM	GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687 (Business Wire)
Sep-05-23 07:00AM	GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference (Business Wire) -5.10%
Aug-17-23 07:00AM	GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-02-23 07:17AM	GlycoMimetics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023 (Business Wire)
Jul-19-23 07:00AM	GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023 (Business Wire) -6.43%
Jul-13-23 09:29AM	12 Best Multibagger Penny Stocks To Buy (Insider Monkey)
08:00AM	Loading…
Jun-26-23 08:00AM	GlycoMimetics Announces Its Addition to the Russell Microcap® Index (Business Wire)
Jun-15-23 08:00AM	GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia (Business Wire) +8.52%
Jun-12-23 11:13AM	We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-31-23 07:00AM	GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference (Business Wire)
May-16-23 10:37AM	retail investors who own 36% along with institutions invested in GlycoMimetics, Inc. (NASDAQ:GLYC) saw increase in their holdings value last week (Simply Wall St.) -6.73%
May-03-23 10:17PM	Q1 2023 GlycoMimetics Inc Earnings Call (Thomson Reuters StreetEvents)
07:23AM	GlycoMimetics: Q1 Earnings Snapshot (AP Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023 (Business Wire)
Apr-26-23 07:00AM	GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023 (Business Wire)
Apr-19-23 10:20AM	Possible turnaround for GlycoMimetics, Inc. (NASDAQ:GLYC) insiders, still down US$63k after a US$732k shopping spree (Simply Wall St.)
Apr-05-23 01:45PM	The Quant Trading System Picking Stocks That Soar 300% (InvestorPlace)
Mar-31-23 04:30AM	GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-29-23 07:00AM	GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022 (Business Wire) -9.29%
Mar-21-23 06:23AM	Daily Vickers Top Insider Picks for 03/21/2023 (Argus Research)
Mar-20-23 06:35AM	Daily Vickers Top Insider Picks for 03/20/2023 (Argus Research)
06:47AM	Loading…
Mar-17-23 06:47AM	Daily Vickers Top Insider Picks for 03/17/2023 (Argus Research) -5.41%
Mar-16-23 07:00AM	GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023 (Business Wire)
06:51AM	Daily Vickers Top Insider Picks for 03/16/2023 (Argus Research)
Mar-15-23 06:44AM	Daily Vickers Top Insider Picks for 03/15/2023 (Argus Research)
Mar-13-23 06:32AM	Daily Vickers Top Insider Picks for 03/13/2023 (Argus Research) +10.69%
Mar-10-23 07:04AM	Daily Vickers Top Insider Picks for 03/10/2023 (Argus Research)
Mar-09-23 06:33AM	Daily Vickers Top Insider Picks for 03/09/2023 (Argus Research) -9.52%
Mar-08-23 06:30AM	Daily Vickers Top Insider Picks for 03/08/2023 (Argus Research)
Mar-07-23 06:34AM	Daily Vickers Top Insider Picks for 03/07/2023 (Argus Research)
Mar-06-23 07:22AM	Daily Vickers Top Insider Picks for 03/06/2023 (Argus Research) -5.13%
Mar-03-23 06:38AM	Daily Vickers Top Insider Picks for 03/03/2023 (Argus Research)
Mar-02-23 06:44AM	Daily Vickers Top Insider Picks for 03/02/2023 (Argus Research)
Mar-01-23 07:00AM	GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care Conference (Business Wire)
06:01AM	Daily Vickers Top Insider Picks for 03/01/2023 (Argus Research)
06:01AM	Daily Vickers Top Buyers & Sellers for 03/01/2023 (Argus Research)
Feb-28-23 06:43AM	Daily Vickers Top Insider Picks for 02/28/2023 (Argus Research)
Feb-27-23 06:50AM	Daily Vickers Top Insider Picks for 02/27/2023 (Argus Research)
Feb-24-23 07:17AM	Daily Vickers Top Insider Picks for 02/24/2023 (Argus Research)
07:17AM	Daily Vickers Top Buyers & Sellers for 02/24/2023 (Argus Research)
Feb-16-23 08:00AM	GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +19.41%
Feb-15-23 08:00AM	GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee (Business Wire) -62.47%
Feb-14-23 06:23AM	Daily Vickers Top Buyers & Sellers for 02/14/2023 (Argus Research) +7.14%
Feb-06-23 07:00AM	GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jan-22-23 07:30AM	This Small Pharma Company Could Develop Into a Nice Trade (TheStreet.com)
07:24AM	GlycoMimetics, Inc.'s (NASDAQ:GLYC) Shift From Loss To Profit (Simply Wall St.)
Dec-30-22 07:17AM	Daily Vickers Top Insider Picks for 12/30/2022 (Argus Research)
Dec-28-22 06:58AM	Daily Vickers Top Buyers & Sellers for 12/28/2022 (Argus Research) +19.20%
Dec-26-22 07:14AM	Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Invest In Growth? (Simply Wall St.)
Dec-19-22 09:40AM	Is Axonics (AXNX) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-12-22 07:00AM	GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting (Business Wire)
Dec-02-22 01:18PM	Individual investors account for 44% of GlycoMimetics, Inc.'s (NASDAQ:GLYC) ownership, while hedge funds account for 18% (Simply Wall St.) +7.01%
09:40AM	Is GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-23-22 09:55AM	After Golden Cross, GlycoMimetics (GLYC)'s Technical Outlook is Bright (Zacks)
Nov-16-22 09:40AM	Are Medical Stocks Lagging Axonics (AXNX) This Year? (Zacks) +9.41%
Nov-12-22 07:14AM	GlycoMimetics Third Quarter 2022 Earnings: US$0.16 loss per share (vs US$0.34 loss in 3Q 2021) (Simply Wall St.)
Nov-10-22 09:12AM	Insiders at GlycoMimetics, Inc. (NASDAQ:GLYC) recouped some losses this week after buying this year, still down US$49k (Simply Wall St.) +19.48%
Nov-09-22 07:00AM	GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022 (Business Wire) +19.32%
Nov-08-22 04:05PM	GlycoMimetics to Participate in Two Upcoming Investor Conferences (Business Wire)
Nov-03-22 09:00AM	GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia Will Be Presented at ASH Annual Meeting (Business Wire)
Nov-02-22 07:00AM	GlycoMimetics to Report Third Quarter Financial Results on November 9, 2022 (Business Wire)
Oct-10-22 11:57PM	BIO Chief Executive Michelle McMurry-Heath Exits After Clashes With Board (The Wall Street Journal)
Oct-04-22 12:00PM	GlycoMimetics (GLYC) Upgraded to Buy: Here's Why (Zacks) +11.31%
Sep-09-22 08:30AM	GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Sep-07-22 07:00AM	GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference (Business Wire)
Sep-06-22 07:00AM	GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer (Business Wire)
Aug-09-22 12:00PM	What Makes GlycoMimetics (GLYC) a New Buy Stock (Zacks) -9.03%
Aug-03-22 02:00PM	GlycoMimetics (GLYC) Q2 2022 Earnings Call Transcript (Motley Fool)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2022 (Business Wire)
Jul-27-22 04:00PM	GlycoMimetics to Report Second Quarter Financial Results on August 3, 2022 (Business Wire)
Jul-18-22 10:22AM	Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely (Simply Wall St.) +10.74%
Jun-03-22 08:36AM	A GlycoMimetics, Inc. (NASDAQ:GLYC) insider increased their holdings last year (Simply Wall St.) +11.77%
Jun-02-22 04:00PM	GlycoMimetics to Participate at Upcoming Jefferies 2022 Healthcare Conference (Business Wire)
Apr-28-22 06:30PM	GlycoMimetics (GLYC) Q1 2022 Earnings Call Transcript (Motley Fool) -7.98%
07:30AM	GlycoMimetics Reports Highlights and Financial Results for First Quarter 2022 (Business Wire)
Apr-25-22 09:00AM	GlycoMimetics to Report First Quarter Financial Results on April 28, 2022 (Business Wire)
Mar-08-22 04:30PM	GlycoMimetics to Participate at Upcoming Roth Investor Conference (Business Wire)
Mar-03-22 04:15PM	GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -19.85%
01:00PM	GlycoMimetics (GLYC) Q4 2021 Earnings Call Transcript (Motley Fool)
07:30AM	GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2021 (Business Wire)
Mar-02-22 09:15AM	GlycoMimetics Appoints Deepak Tiwari, Ph.D., as new Vice President, Technical Operations (Business Wire) +7.09%
Feb-25-22 09:00AM	GlycoMimetics to Report Fourth Quarter and 2021 Year-End Financial Results on March 3, 2022 (Business Wire) +6.25%
Feb-23-22 04:30PM	GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
04:00PM	GlycoMimetics Appoints Bruce Johnson Senior Vice President and Chief Commercial Officer (Business Wire)
Dec-13-21 09:00AM	Two GlycoMimetics Posters at 63rd ASH Annual Meeting Highlight Potential of GMI-1359, a Dual Antagonist of CXCR4 and E-selectin (Business Wire)
Dec-06-21 09:15AM	NCI-Sponsored Trial of Uproleselan in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Completes Enrollment of Phase 2 Portion Ahead of Schedule (Business Wire)
Nov-24-21 08:00PM	GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Nov-23-21 04:30PM	Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial in China of GlycoMimetics Uproleselan for the Treatment of AML (Business Wire)
Nov-22-21 04:15PM	GlycoMimetics Appoints Regulatory Veteran Lisa DeLuca as Vice President, Regulatory Affairs (Business Wire)
Nov-15-21 07:00AM	GlycoMimetics Completes Enrollment of Phase 3 Registration Trial Evaluating Lead Candidate Uproleselan in Patients with Relapsed /Refractory Acute Myeloid Leukemia (AML) (Business Wire)
Nov-11-21 09:00AM	GlycoMimetics GMI-1359 Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting and Exposition (Business Wire)

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rock Edwin	Chief Medical Officer	Sep 22	Buy	1.38	30,403	41,956	375,403	Sep 25 04:21 PM
Rock Edwin	Chief Medical Officer	Sep 21	Buy	1.38	35,000	48,300	345,000	Sep 25 04:21 PM
Koenig Scott	Director	Jun 01	Option Exercise	0.60	21,000	12,600	36,750	Jun 02 04:10 PM
Hahn Brian M.	SVP Finance, CFO	May 17	Sale	1.95	3,700	7,215	53,143	May 18 04:27 PM
JUNIUS DANIEL M	Director	May 10	Buy	1.56	30,000	46,800	93,250	May 11 05:08 PM
Johnson Bruce S	SVP & Chief Commercial Officer	May 08	Buy	1.57	13,500	21,195	138,980	May 09 05:00 PM
Invus Public Equities, L.P.	10% Owner	Feb 23	Buy	1.75	200,000	350,760	8,489,064	Feb 23 06:23 PM
Invus Public Equities, L.P.	10% Owner	Feb 22	Buy	1.79	150,000	268,995	8,289,064	Feb 23 06:23 PM
Invus Public Equities, L.P.	10% Owner	Feb 21	Buy	1.85	50,000	92,500	8,139,064	Feb 23 06:23 PM
Invus Public Equities, L.P.	10% Owner	Feb 17	Buy	1.71	200,000	341,000	8,089,064	Feb 17 05:29 PM
Invus Public Equities, L.P.	10% Owner	Feb 16	Buy	1.68	315,266	531,129	7,889,064	Feb 17 05:29 PM
Invus Public Equities, L.P.	10% Owner	Feb 15	Buy	2.16	1,000,000	2,155,800	7,573,798	Feb 17 05:29 PM
Invus Public Equities, L.P.	10% Owner	Feb 09	Buy	3.24	11,451	37,123	6,573,798	Feb 13 05:45 PM
Koenig Scott	Director	Jan 27	Option Exercise	2.55	10,500	26,775	15,750	Jan 30 04:13 PM
SANDELL SCOTT D	10% Owner	Jan 26	Sale	3.12	3,000,000	9,356,400	2,237,196	Jan 27 05:15 PM
SANDELL SCOTT D	10% Owner	Jan 25	Sale	3.26	652,016	2,128,115	3,588,288	Jan 27 05:15 PM
SANDELL SCOTT D	10% Owner	Jan 05	Sale	2.76	71,362	196,859	3,881,933	Jan 06 06:35 PM
SANDELL SCOTT D	10% Owner	Jan 04	Sale	2.91	101,984	296,743	3,914,072	Jan 04 05:26 PM
SANDELL SCOTT D	10% Owner	Jan 03	Sale	2.99	174,814	522,711	3,960,002	Jan 04 05:26 PM
SANDELL SCOTT D	10% Owner	Dec 30	Sale	3.02	121,335	366,432	4,038,732	Jan 04 05:26 PM
Rock Edwin	Chief Medical Officer	Dec 22	Buy	2.25	110,000	247,500	310,000	Dec 27 06:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GLYC

GlycoMimetics Inc

Upgrade your FINVIZ experience